Histamine Dihydrochloride

Clinical trials investigating Histamine Dihydrochloride are studying different uses in people with allergies and pancreatic cancer. These studies look at goals such as test accuracy, clinical benefit, safety, and tolerability. The target groups include patients with specific pollen, mite, or food allergies, as well as people with pancreatic cancer.

Table of contents

Trial overview

Across the trial data, Histamine Dihydrochloride appears mainly as a reference substance in allergy skin prick tests, where it is used as a positive control to compare skin reactions.[1][2] The studies focus on whether allergen extracts from mites, grasses, birch, olive, and other sources produce a wheal similar to the one caused by Histamine Dihydrochloride at 10 mg/mL.[1][2] One separate trial studies a treatment approach in pancreatic cancer and includes Histamine Dihydrochloride in the trial context through the provided data set.[3]

Allergy testing studies using Histamine Dihydrochloride

Several Phase 2 trials use Histamine Dihydrochloride as a comparison point in prick tests, which are skin tests that help show whether a person reacts to a specific allergen.[1][4] These studies look at the biological standardization of allergen extracts, which means they try to measure and compare the strength of different extracts in a consistent way.[1][4]

The allergy-related trials include studies of:

  • Blomia tropicalis allergen extract, where the goal is to find the concentration that gives a wheal similar to a 10 mg/mL Histamine Dihydrochloride solution.[1]

  • Lepidoglyphus destructor allergen extract, with the same type of comparison against Histamine Dihydrochloride.[2]

  • Dermatophagoides mite extracts, including Dermatophagoides pteronyssinus and Dermatophagoides farinae, again using the wheal response compared with Histamine Dihydrochloride at 10 mg/mL.[4][5]

  • Phleum pratense and Dactylis glomerata pollen extracts, where the study measures wheal size after prick testing and compares it with the histamine positive control.[6]

These studies are not mainly testing Histamine Dihydrochloride as a treatment. Instead, they use it as a known skin reaction marker so researchers can judge how strong the allergen extracts are.[1][4]

Pancreatic cancer study

One Phase 1 trial, called PANCEP-1, studies pancreatic cancer and evaluates the safety and tolerability of the treatment by collecting adverse events and other safety data.[3] The trial includes people with pancreatic cancer and follows safety from Cycle 1 Day 1 through the final study visit.[3]

The trial measures adverse events, their severity, and whether they are related to treatment, and it also uses laboratory tests, physical exams, and other safety checks.[3] In the source data, the intervention list includes PROLEUKIN® and Ceplene, and the study is designed to assess the frequency and extent of adverse events linked to the therapy.[3]

Who participates in these trials

The allergy trials recruit people with specific allergies, such as allergy to mites, grass pollen, birch pollen, olive pollen, or peanut allergy in young children.[1][4][6][7] Some trials also include children and adolescents with seasonal allergic rhinitis or rhinoconjunctivitis, which means ongoing allergy symptoms affecting the nose and sometimes the eyes.[7][8]

Other studies focus on adults with moderate to severe allergic rhinitis or rhinoconjunctivitis caused by house dust mite, birch pollen, grass pollen, or olive pollen exposure for at least two years according to the ARIA guideline.[5][7][8][9] The pancreatic cancer trial includes people with pancreatic cancer.[3]

Phases and main endpoints

Most of the Histamine Dihydrochloride-related allergy studies are Phase 2 trials, which usually means they are focused on finding the right test conditions and checking how well a method works in a group of patients.[1][2][4] The peanut allergy and pollen immunotherapy studies are mainly Phase 3 trials, which compare active treatment with placebo in larger groups.[7][8][9][10]

The main endpoints in the allergy extract studies are the wheal area in square millimeters and the dose-response relationship, meaning how the skin reaction changes as the concentration changes.[1][4] Several studies also try to find the theoretical concentration of extract that gives a reaction equal to Histamine Dihydrochloride at 10 mg/mL.[1][2][4][6]

In the larger allergy treatment trials, the main outcomes are symptom and medication scores such as CSMS and TCRS, which combine how bad the symptoms are with how much medicine is needed.[5][7][8][9] The peanut allergy trial measures treatment responders after 12 months, while also tracking safety events, local skin reactions, and other serious reactions.[10]

What the study measures mean

A wheal is the raised bump that can appear on the skin after a prick test, and its size helps show how strong the reaction is.[1][4] A larger wheal usually means a stronger skin reaction, so researchers measure it carefully in these trials.[1][4]

A positive control is a test substance expected to cause a reaction, and Histamine Dihydrochloride is used in that role in several studies.[1][2][4][6] A negative control is a substance that should not cause a reaction, which helps show whether the test result is reliable.[1][4]

The term biological standardization means checking and comparing the activity of allergen extracts in living people so the extracts can be measured in a consistent way.[1][4] This helps researchers decide whether different extract concentrations behave as expected when compared with Histamine Dihydrochloride.[1][2][4]

Trial ID Phase Condition studied Status Enrollment
2024-513834-40-01 Phase 2 Allergies; mite allergen extract standardization with Histamine Dihydrochloride comparator Completed 90
2024-514215-98-00 Phase 2 Allergy to Phleum pratense and Dactylis glomerata Completed 30
2025-520711-14-00 Phase 2 Allergies; Blomia tropicalis extract standardization Authorised 36
2025-520753-37-00 Phase 2 Allergies; Lepidoglyphus destructor extract standardization Authorised 36
2025-523866-26-00 Phase 2 Allergies; Olea europaea extract standardization Authorised 36
2023-509541-13-00 Phase 2 Allergy to Lepidoglyphus destructor Completed 30
2024-515169-33-00 Phase 2 Allergy to Blomia tropicalis Authorised 30
2024-514108-15-00 Phase 2 Allergies; Dermatophagoides extract standardization Withdrawn 96
2024-514108-15-01 Phase 2 Allergies; Dermatophagoides extract standardization Authorised 60
2024-514215-98-00 Phase 2 Allergy to Phleum pratense and Dactylis glomerata Completed 30
2023-506979-10-00 Phase 1 Pancreatic cancer Authorised 50

Ongoing Clinical Trials on Histamine Dihydrochloride

  • Study on Allergy to Lepidoglyphus Destructor: Testing with Lepidoglyphus Destructor Extract, Histamine Hydrochloride, and Sodium Chloride in Affected Patients

    Not recruiting

    1 1
    Spain
  • Study on Allergenic Extracts of Mites and Histamine Dihydrochloride for Allergy Patients

    Not recruiting

    1 1
    Investigated diseases:
    Spain
  • Study on Allergy to Phleum pratense and Dactylis glomerata: Testing Reactions to Phleum pratense and Dactylis glomerata Pollen Extracts in Patients with Allergies

    Not recruiting

    1 1
    Spain
  • Study on the Effectiveness and Safety of Allergenic Extract of Olea Europaea Pollen for Patients with Moderate-to-Severe Olive Pollen Allergy

    Not recruiting

    1 1 1
    Spain
  • Study on the Effectiveness and Safety of Phleum Pratense Pollen Extract for Patients with Moderate-to-Severe Grass Pollen Allergy

    Not recruiting

    1 1 1
    Investigated diseases:
    Germany
  • Study on the Effectiveness of PURETHAL Mites for Adults with Moderate to Severe Allergic Rhinitis or Rhinoconjunctivitis Due to House Dust Mite Allergy

    Not recruiting

    1 1 1
    Austria Bulgaria Germany Latvia Lithuania Poland
  • Study on the Effectiveness and Safety of DBV712 for Peanut Allergy in Children Aged 4-7

    Not recruiting

    1 1 1
    France Germany Ireland The Netherlands Spain
  • Study on the Effectiveness and Safety of Sublingual Immunotherapy with Betula Pendula Pollen Extract for Patients with Birch Pollen Allergy

    Not recruiting

    1 1 1
    Investigated diseases:
    Germany
  • Study on the Effects of Mannan-Conjugated Birch Pollen Allergoids for Adolescents and Adults with Birch Pollen-Induced Allergic Rhinitis or Rhinoconjunctivitis

    Not recruiting

    1 1 1
    Germany

Glossary

  • Clinical trial: A research study in people that tests whether a medical approach is safe, works well, or both.
  • Phase 1: An early trial phase that mainly checks safety and tolerability in a small group.
  • Phase 2: A trial phase that looks more closely at whether a test or treatment works and how it performs in a group of patients.
  • Phase 3: A larger trial phase that compares a treatment with placebo or another treatment to confirm benefit and safety.
  • Prick test: A skin test where a small amount of allergen is placed on the skin and the skin is lightly pricked to see if a reaction appears.
  • Wheal: A raised bump on the skin that can appear after an allergy test.
  • Positive control: A known substance that should cause a reaction in a test, used to make sure the test is working.
  • Negative control: A substance that should not cause a reaction, used for comparison in a test.
  • Allergic rhinitis: Nasal allergy that can cause sneezing, runny nose, and congestion.
  • Rhinoconjunctivitis: Allergy symptoms that affect both the nose and the eyes.
  • CSMS: Combined Symptom and Medication Score, a score that adds together allergy symptoms and the need for medicine.
  • TCRS: Total Combined Rhinitis Score, a score used to measure rhinitis symptoms over time.

References

  1. https://clinicaltrials.gov/study/2024-515169-33-00
  2. https://clinicaltrials.gov/study/2023-509541-13-00
  3. https://clinicaltrials.gov/study/2023-506979-10-00
  4. https://clinicaltrials.gov/study/2024-513834-40-01
  5. https://clinicaltrials.gov/study/2025-520711-14-00
  6. https://clinicaltrials.gov/study/2024-514215-98-00
  7. https://clinicaltrials.gov/study/2023-505880-35-00
  8. https://clinicaltrials.gov/study/2023-505567-37-00
  9. https://clinicaltrials.gov/study/2024-515717-17-00
  10. https://clinicaltrials.eu/trial/study-on-the-effectiveness-and-safety-of-dbv712-for-peanut-allergy-in-children-aged-4-7/